New editorial
Key facts about the Bundibugyo virus outbreak
www.thelancet.com/journals/lan...
Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda: rapid assessment from the ESCMID Emerging Infections Subcommittee
@cmijournal.bsky.social
@escmid.bsky.social
www.clinicalmicrobiologyandinfection.org/article/S119...
Alveolar dysregulation of host response in pneumonia and ARDS: implications for immune modulation and infection
CCR Journal Watch
https://criticalcarereviews.com/latest-evidence/journal-watch
The ongoing outbreak of Ebola virus disease (EVD) caused by Bundibugyo ebolavirus
(BDBV) in the Democratic Republic of the Congo (DRC) and Uganda represents a major
regional public health emergency wi...
Congrats to my colleagues for this interesting analysis.
Looking at patients who met DOTS criteria and receive dalbavancin in our hospital, they differ from the DOTS trial
Younger, more IDU, more R-sided IE (less SSTI), and more persistent bacteremia.
Yet, outcomes similar #IDSky
The Lancet Infectious Diseases
Jesús Rodríguez Baño
📣 New publication: First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib: www.clinicalmicrobiologyandinfection.org/article/S119...
#hantavirus
The Emerging Infections Subcommittee just published in CMI a rapid assessment of the Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda, covering the current situation and key challenges. https://ow.ly/rS5s50Z60wO
Critical Care Reviews
🎙️ A special bonus episode of #Communicable is coming Monday
Angela Huttner & Anne-Grete Märtson talk with Daniel Bausch & Martin Grobusch on how #Bundibugyo ebolavirus differs from Zaire & what to expect in the current outbreak
#IDSky #Virosky #clinmicro
https://ow.ly/nm5250Z7ViE
In clinical practice, patients with #Bacteremia receiving dalbavancin were younger and more likely to have substance use or housing instability than those in the DOTS trial, but completed therapy with similar low failure rates. ja.ma/4odctAk
🎙️ Just published Communicable E54: ESCMID Global Late Breakers, part 2
Hosted by our editors - Erin McCreary, PharmD, Josh Davis, Marc Bonten, Anne-Grete Märtson, Angela Huttner 🌟
Listen on #Communicable: https://share.transistor.fm/s/a8cc04bb
#ESCMIDGlobal2026 #IDSky #clinmicro
In this latest @escmid.bsky.social clinical guideline, a panel of 16 multidisciplinary experts provide recommendations for how to evaluate and manage patients with reported antibiotic allergies.
www.clinicalmicrobiologyandinfection.org/article/S119...
Jonathan Ryder, MD
Clinical Microbiology and Infection
Clinical Microbiology and Infection
JAMA Network Open
ESCMID
CMI Communications
CMI Communications
On May 15, 2026, an outbreak of Ebola virus disease (EVD) was declared in DRC and
Uganda, with WHO designating it a Public Health Emergency of International Concern
on May 17. The outbreak is due to B...
In clinical practice, patients with #Bacteremia receiving dalbavancin were younger and more likely to have substance use or housing instability than those in the DOTS trial, but completed therapy with similar low failure rates. ja.ma/4odctAk
